Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology

Executive Summary

The competitive bidding process for Medivation shows just how much big pharma is willing to pay for commercial-stage oncology assets. Now that Pfizer has won the biotech, it will have to prove Xtandi is worth the price.

Advertisement

Related Content

Myovant On Path To Women’s Health Leadership, CEO Says
Big Pharma Is Back In The M&A Driver’s Seat For 2017
Will Sanofi Overpay For Actelion Innovation Or, Like J&J, Also Walk Away?
Pfizer’s Avelumab Poised For Speedy Review By FDA
Biopharma Quarterly Dealmaking Statistics, Q3 2016
With Medivation, Pfizer Sees A Chance For More Combinations
Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations
Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole
Mylan Turns To Meda In Sweden For Open Door Into Consumer Market
Medivation/Astellas’ Xtandi A Tough Rival For J&J’s Zytiga

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register